SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data

COPD is a major cause of mortality in the western world. A 2A agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A 2A agonists dictate that a compound needs to be delivered by inhalation to be therapeutically useful. The pharmacological and pharmacokinetic SAR of a series of inhaled A 2A agonists is described leading through to human pharmacokinetic data for a clinical candidate.